Cutaneous Toxicities of Cancer Immunotherapy

Immune checkpoint inhibitors are transforming oncology—but their high rate of cutaneous immune-related adverse events (cirAEs) poses both diagnostic and management challenges for clinicians. This session will explore the diverse spectrum of skin toxicities—from common maculopapular rashes and lichenoid eruptions to rare but serious reactions like Stevens–Johnson syndrome—that can be associated with cancer immunotherapy. Attendees will also be provided with practical guidelines for early recognition, grading, and treatment to ensure continuation of life-saving therapies whenever possible.